<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02526875</url>
  </required_header>
  <id_info>
    <org_study_id>330HT14009</org_study_id>
    <nct_id>NCT02526875</nct_id>
  </id_info>
  <brief_title>Efficacy of a Telmisartan/S-Amlodipine on 24-hour BP Control in Hypertensive Patients Inadequately Controlled</brief_title>
  <official_title>A Multicenter, Prospective, Randomized, Open-label, Phase 4 Trial Designed to Evaluate the Efficacy of a Telmisartan/S-Amlodipine(Telminuvo®Tab. 40/2.5mg) on 24-hour BP Control in Hypertensive Patients Inadequately Controlled</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To Evaluate the Efficacy of the Timing of the Administration of a Telmisartan/S-Amlodipine
      (Telminuvo®Tab. 40/2.5mg) on 24-hour BP Control in Hypertensive Patients Inadequately
      Controlled by Telmisartan Monotherapy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Multicenter, Prospective, Randomized, Open-label, Phase 4 Trial Designed to Evaluate the
      Efficacy of the Timing of the Administration of a Telmisartan/S-Amlodipine(Telminuvo®Tab.
      40/2.5mg) on 24-hour BP Control in Hypertensive Patients Inadequately Controlled by
      Telmisartan Monotherapy
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">November 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in the 24hr mean blood pressure by ambulatory blood pressure monitoring(ABPM) at week 8.</measure>
    <time_frame>Baseline and week 8</time_frame>
    <description>Change from baseline in the 24hr mean blood pressure by ambulatory blood pressure monitoring(ABPM) at week 8.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the 24hr mean daytime, nighttime, morning blood pressure by ABPM at week 8</measure>
    <time_frame>Baseline and week 8</time_frame>
    <description>Daytime: 06:00~21:59
Nighttime: 22:00~05:59
Morning: 06:00~11:59</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the clinic mean blood pressure at week 8.</measure>
    <time_frame>Baseline and week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24hr ABPM and Clinic BP control at week 8.</measure>
    <time_frame>Baseline and week 8</time_frame>
    <description>&lt;24hr ABPM&gt;
24hr mean BP: 24hr mean Systolic blood pressure(SBP)&lt;130mmHg and 24hr mean Diastolic blood pressure(DBP)&lt;80mmHg
Daytime BP: Daytime mean SBP&lt;135mmHg and Daytime mean DBP&lt;85mmHg
Night time BP: Night time mean SBP&lt;120mmHg and Night time mean DBP&lt;70mmHg
&lt;Clinic BP&gt;
: Mean sitting systolic blood pressure&lt;140mmHg and Mean sitting diastolic blood pressure&lt;90mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morning BP Surge</measure>
    <time_frame>Baseline and week 8</time_frame>
    <description>The morning BP surge was calculated as the morning BP minus the lowest BP. Morning BP was defined as the average BP during the first 2 h after waking. The lowest BP was defined as the average of three BP readings focused on the lowest night-time reading (that is, the lowest reading plus the readings immediately before and after)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">208</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>night</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Telminuvo®Tab. 40/2.5mg ,Once daily, from 6 pm to 10 pm, Per oral for 8weeks after 2~4weeks run-in period with Telmitrend®Tab. 40mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>morning</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Telminuvo®Tab. 40/2.5mg ,Once daily, from 6 am to 10 am, Per oral for 8weeks after 2~4weeks run-in period with Telmitrend®Tab. 40mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telminuvo®Tab. 40/2.5mg</intervention_name>
    <description>per oral for 8weeks after 2~4weeks run-in period with Telmitrend®Tab. 40mg</description>
    <arm_group_label>night</arm_group_label>
    <arm_group_label>morning</arm_group_label>
    <other_name>Telmisartan/S-Amlodipine 40/2.5mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. More than 20 years in hypertension patient

          2. Hypertension is satisfied with the Clinic blood pressure that was measured at the time
             of screening

               -  Treatment-Naive: Clinic Mean sitting diastolic blood pressure ≥ 100mmHg.

               -  Treatment-Experienced: Clinic Mean sitting diastolic blood pressure ≥ 90mmHg.

          3. Hypertension is satisfied with the Clinic blood pressure that was measured at the time
             of randomization

               -  Clinic Mean sitting diastolic blood pressure ≥ 90mmHg

          4. Patient who decided to participate and signed on an informed consent form willingly

        Exclusion Criteria:

          1. Clinic Mean sitting systolic blood pressure ≥ 180mmHg or Clinic Mean sitting diastolic
             blood pressure ≥ 115mmHg at the time of Screening and Randomization

          2. As night workers who sleep during the day and whose working hours including 00:00 to
             04:00

          3. Secondary Hypertension

          4. Severe heart disease(Heart failure; New York Heart Association(NYHA) class 3, 4) and
             recent unstable angina or myocardial infarction or valvular heart disease or
             arrhythmia requiring treatment within the past 3 months

          5. Severe cerebrovascular disorders such as cerebral infarction, cerebral hemorrhage
             within 6 months

          6. type 1 diabetes mellitus or Uncontrolled type 2 diabetes mellitus(HbA1c &gt; 8.0%)

          7. Severe or malignant retinopathy

          8. Abnormal laboratory test results

               -  Aspartate aminotransferase/Alanine aminotransferase &gt; Upper normal limit X 2

               -  Serum creatinine &gt; Upper normal limit X 2

          9. Acute of chronic inflammatory status requiring treatment

         10. Need for other antihypertensive drugs during the trial

         11. Need for prohibited medication specified in the protocol

         12. A history of angioedema with ACE inhibitors or angiotensin-Ⅱ receptor blockers

         13. Severe hypersensitivity to amlodipine or telmisartan

         14. History of drug or alcohol abuse within 6 months

         15. Surgical or medical conditions

               -  History of major gastrointestinal surgery

               -  History of active inflammatory bowel syndrome within 12 months

               -  Abnormal pancreatic functions

               -  Gastrointestinal/rectal bleeding

               -  Urinary tract obstruction

         16. Administration of other Investigational Product within 30 days

         17. Pregnant, breast-feeding and childbearing age who don't use adequate contraception

         18. History of malignant tumor within 5 years (including leukemia and lymphoma)

         19. Another clinical condition in investigator's judgement
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dong-Gu Shin</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yeungnam University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dong-Gu Shin</last_name>
    <phone>82-53-620-3843</phone>
    <email>dgshin@med.yu.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Korean University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Guro-gu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin-Won Kim</last_name>
      <phone>82-2-2626-3021</phone>
      <email>kjwmm@korea.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Myongji Hospital</name>
      <address>
        <city>Goyang</city>
        <state>Gyeonggi-di</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tae-Young Choi</last_name>
      <phone>82-31-810-6773</phone>
      <email>tchoicardio@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inje University Ilsan Paik Hospital</name>
      <address>
        <city>Goyang</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sung-Wook Kwon</last_name>
      <phone>82-31-910-7041</phone>
      <email>mdksu@yahoo.co.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bundang Jesaeng Hospital</name>
      <address>
        <city>Seongnam</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sung-Wook Cho</last_name>
      <phone>82-31-779-0379</phone>
      <email>cswim@dmc.or.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Daegu Catholic University Medical Center</name>
      <address>
        <city>Dae-gu</city>
        <state>Gyeongsangbuk-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young-Su Lee</last_name>
      <phone>82-53-650-4797</phone>
      <email>mdleeys@cu.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Medical Center</name>
      <address>
        <city>Daegu</city>
        <state>Gyeongsangbuk-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyeong-Seop Park</last_name>
      <phone>82-53-250-7473</phone>
      <email>drparkgyver@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yeungnam University Medical Center</name>
      <address>
        <city>Daegu</city>
        <state>Gyeongsangbuk-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dong-Gu Shin</last_name>
      <phone>82-53-620-3843</phone>
      <email>dgshin@med.yu.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cheju Halla General Hospital</name>
      <address>
        <city>Jeju</city>
        <state>Jeju Special Self-Governing</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seung-Ho Kang</last_name>
      <phone>82-64-740-5002</phone>
      <email>metronics@paran.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dong-A University Hospital</name>
      <address>
        <city>Busan</city>
        <state>Seo-gu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jong-Sung Park</last_name>
      <phone>82-51-240-2764</phone>
      <email>thinkmed@dau.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Busan</city>
        <state>Seo-gu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kwang-Su Cha</last_name>
      <phone>82-51-240-7221</phone>
      <email>chakws1@hanmail.net</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2015</study_first_submitted>
  <study_first_submitted_qc>August 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2015</study_first_posted>
  <last_update_submitted>August 18, 2017</last_update_submitted>
  <last_update_submitted_qc>August 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hypertension, Telmisartan/S-Amlodipine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

